Rigel Pharmaceuticals, Inc.

RIGL

US7665597024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
9.98 ^USD	+3.74%		+28.28%	-31.17%

Jun. 25	Rigel Pharmaceuticals to Implement 1-for-10 Reverse Stock Split	MT
Jun. 25	Sector Update: Health Care Stocks Advance Pre-Bell Tuesday	MT

Rigel Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter of 2020

January 11, 2021 at 04:34 pm EST

Rigel Pharmaceuticals, Inc. provided revenue guidance for the fourth quarter of 2020. For the fourth quarter 2020, the company expects to report total revenue of approximately $18.4 million.

Latest news about Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals to Implement 1-for-10 Reverse Stock Split	Jun. 25	MT
Sector Update: Health Care Stocks Advance Pre-Bell Tuesday	Jun. 25	MT
Rigel Pharmaceuticals Completes Transfer of Gavreto New Drug Application	Jun. 24	MT
Rigel Pharmaceuticals Completes Transfer of GAVRETO®? (pralsetinib) New Drug Application	Jun. 24	CI
Rigel Pharmaceuticals, Inc. Announces Five Presentations at the EHA2024 Hybrid Congress	Jun. 14	CI
Transcript : Rigel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $29.5M, vs. Street Est of $31.5M	May. 07	MT
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Rigel Pharmaceuticals, Inc. Enters into Amendment No. 4 to that Certain Credit and Security Agreement	Apr. 12	CI
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer	Mar. 12	CI
Citigroup Adjusts Rigel Pharmaceuticals' Price Target to $4 From $3, Maintains Buy Rating	Mar. 07	MT
Transcript : Rigel Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 05, 2024	Mar. 05
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q4 Revenue $35.8M, vs. Street Est of $33.4M	Mar. 05	MT
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 05	CI
B. Riley Lifts Rigel Pharmaceuticals' PT to $1.75 From $1.25 After Announced Purchase of US Rights to Gavreto From Blueprint Medicines; Keeps Neutral Rating	Feb. 26	MT
Rigel Pharmaceuticals Seeks Acquisitions	Jan. 11	CI
Transcript : Rigel Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 12:00 PM	Jan. 11
Rigel Pharmaceuticals Enters Collaboration to Study Possible Treatment for Brain Tumors; Shares Rise	Jan. 04	MT
Rigel Pharmaceuticals, Inc. Announces Collaboration with Connect to Conduct a Phase 2 Trial of Olutasidenib in Glioma	Jan. 04	CI
Rigel Pharmaceuticals, MD Anderson Partner for Research on New Rezlidhia Indications	Dec. 08	MT
Rigel Pharmaceuticals, Inc. and The University of Texas MD Anderson Cancer Center Announce Strategic Alliance to Advance REZLIDHIA®? (Olutasidenib) in AML and Other Cancers	Dec. 08	CI
B. Riley Trims Rigel Pharmaceuticals' PT to $1.25 From $1.75, Lowers Peak Sales Estimate for Rezlidhia; Maintains Neutral Rating	Nov. 09	MT
Transcript : Rigel Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q3 Revenue $28.1M, vs. Street Est of $27.2M	Nov. 07	MT

Chart Rigel Pharmaceuticals, Inc.

Duration

Period

More charts

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.

Sector

Biotechnology & Medical Research

Calendar

2024-07-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Rigel Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.62 USD

Average target price

20.33 USD

Spread / Average Target

+111.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RIGEL PHARMACEUTICALS, INC.	-31.17%	169M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	127B
REGENERON PHARMACEUTICALS, INC.	+25.25%	117B
ARGENX SE	+25.56%	27.77B
BIONTECH SE	-19.51%	20.44B
GENMAB A/S	-14.36%	16.62B
BEIGENE, LTD.	-15.63%	15.92B
WUXI APPTEC CO., LTD.	-46.67%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.74B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs